Methods and means for the treatment of immune-related diseases
OwnerYpke van Oosterhout, Janny van Emstinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides novel means and methods for treating unwanted side effects in transplantations, such as GVHD and allograft rejection. The invention provides immunotoxins comprising an antibody and a toxic substance, whereby cocktails of such conjugates are directed to different targets associated with one population of cells, wherein one target is chosen from CD3 or CD7. The preferred combination is a cocktail directed against both CD3 and CD7.
Claims20
A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting of:
- first molecules directed against CD3;
- and
- second molecules, distinct from said first molecules, said second molecules targeting CD7, wherein at least one of said first and said second molecules include a toxic moiety.
A method of treating a disease state in a subject believed to be suffering therefrom, said disease state selected from at least one of the group consisting of:
- Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting of:
- first molecules directed against a CD3 positive cell;
- and
- second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety.
A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting of:
- anti-CD3 antibodies;
- and
- anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
A method of treating a disease state in a subject believed to be suffering therefrom, said disease state selected from at least of the group consisting of:
- Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting of:
- anti-CD3 antibodies;
- and
- anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
Dependencies are inferred from the claim text.